Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hodgkin Disease × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 11 Breast Neoplasms 11 Urinary Bladder Neoplasms 10 Neoplasm Metastasis 10 Carcinoma, Merkel Cell 8 Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Head and Neck Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 4 Neuroendocrine Tumors 4 Triple Negative Breast Neoplasms 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma, Hepatocellular 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 154 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 80 Etoposide 77 Mycophenolic Acid 74 Whole-Body Irradiation 71 Melphalan 62 fludarabine 59 Tacrolimus 59 Filgrastim 59 Busulfan 58 Radiotherapy 52 Doxorubicin 50 Rituximab 49 Cyclosporine 47 Brentuximab Vedotin 44 Antilymphocyte Serum 40 Vinblastine 38 Granulocyte Colony-Stimulating Factor 37 Gemcitabine 34 Dacarbazine 33 Methotrexate 32 Cytarabine 32 Bleomycin 28 Nivolumab 26 Carmustine 26 Vincristine 24 Sirolimus 24 Prednisone 24 Bendamustine Hydrochloride 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡